News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Schramm Vern Lee
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/03/2022 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Granted 34,482 options to buy
@ $1.45, valued at
$50k
|
|
| 01/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/07/2020 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 80,000 options
@ $0.97, valued at
$77.6k
|
|
| 03/13/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/01/2019 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 7,500 shares
@ $0.6, valued at
$4.5k
|
|
| 07/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2019 |
4/A
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 30,000 options
@ $1.75, valued at
$52.5k
|
|
| 06/17/2019 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 30,000 shares
@ $0 |
|
| 04/29/2019 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 7,500 shares
@ $2.42, valued at
$18.2k
|
|
| 01/02/2019 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 7,500 shares
@ $1.29, valued at
$9.7k
|
|
| 10/01/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/16/2018 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 7,500 shares
@ $0 |
|
| 04/02/2018 |
4
| Schramm Vern Lee (Director) has filed a Form 4 on AzurRx BioPharma, Inc.|
Txns:
| Granted 7,500 shares
@ $3.14, valued at
$23.6k
|
|
| 10/17/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|